2 completed, 2 unknown. 2 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Unknown 1 |
| Phase 4 | 1 | Unknown 1 |
Follow Bod Australia: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The CANabidiol Use for RElief of Short Term Insomnia 50 mg Cannabidiol (CBD), Placebo, 100 mg Cannabidiol (CBD) - Sleep Disturbance, Insomnia | Phase 2 | Completed | Bod Australia | 208 | 2022-05-01 | 2023-08-16 |
| Feasibility of Cannabidiol for the Treatment of Long COVID MediCabilis Cannabis sativa 50 - Long COVID | Phase 2 | Completed | Bod Australia | 12 | 2022-04-14 | 2023-01-19 |
| EMERALD TRIAL Open Label Extension Study MediCabilis CBD oil - Amyotrophic Lateral Sclerosis, Cannabis | Phase 4 | Unknown | Gold Coast Hospital and Health Service | 7 | 2021-05-17 | 2023-04-03 |
| Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease MediCabilis CBD Oil, Placebo Oil - Amyotrophic Lateral Sclerosis, Motor Neuron Disease | Phase 3 | Unknown | Gold Coast Hospital and Health Service | 17 | 2019-01-09 | 2023-04-03 |
Amyotrophic Lateral Sclerosis (2) · Motor Neuron Disease (2) · Anxiety Disorders (1) · Fatigue (1) · Marijuana Abuse (1) · Parasomnias (1) · Post-Acute COVID-19 Syndrome (1) · Psychological Well-Being (1) · Sleep Initiation and Maintenance Disorders (1) · Sleep Wake Disorders (1)
Cannabidiol (1) · Capsules (1)
Australia (3) · United Kingdom (1)
Elizabeth Iveson (1) · Ron Grunstein (1)